Value proposition

Personalizing Cancer Treatment with Predictive Radiotherapy Tests

Personalizing Cancer Treatment with Predictive Radiotherapy Tests.

At NovaGray, we are committed to transforming the way breast and prostate cancer patients experience radiotherapy by personalizing treatment and minimizing risks.

We are a pioneering French company, spin-off from the leading cancer ICM based in Montpellier, specializing in the development of the first-ever predictive tests for radiotherapy tolerance. These tests, designed for breast and prostate cancer patients, are a major step forward in precision medicine.

How It Works:
Before beginning radiotherapy, with just a simple blood test 🩸, NovaGray assesses a patient’s unique radiosensitivity. This helps predict their risk of developing severe complications post-treatment.

Why It Matters:
One of the greatest challenges in clinical radiobiology is predicting how an individual patient will respond to radiotherapy.

NovaGray’s innovative tests directly address this by:
- Reassuring patients and physicians: Providing confidence in the treatment plan.
- Enabling personalized care: Assisting physicians in choosing the most appropriate treatment path.
- Enhancing post-treatment follow-up: Tailoring care and monitoring based on individual risk.

By helping predict a patient’s response to radiotherapy, we empower clinicians to offer safer, more personalized cancer care, improving outcomes and patient well-being.